# Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

> **NCT00214110** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 100 (—)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00214110
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 100 (—)
- **Last updated:** 2015-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00214110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00214110, "Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00214110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*